The global colorectal cancer screening market size was valued at USD 16.1 billion in 2025 and is projected to grow from USD 17.39 billion in 2026 to USD 32.18 billion by 2034, registering a CAGR of 8% during the forecast period from 2026 to 2034. North America dominated the colorectal cancer screening market with a market share of 38.4% in 2025.
Colorectal cancer screening includes tests and procedures used to detect colorectal cancer or precancerous changes before symptoms appear. Common methods include colonoscopy, stool-based tests, sigmoidoscopy, and imaging techniques. Screening helps identify the disease at an earlier stage when treatment can be more effective. Demand is growing due to rising colorectal cancer cases, greater awareness of early detection, and expanding screening programs.
Download a Free Sample To learn more about this report,
Increasing Adoption of Non-Invasive and At-Home Screening Methods
The colorectal cancer screening market is shifting toward screening approaches that reduce procedural burden and allow patients to complete testing outside traditional endoscopy settings. Stool-based tests can be completed at home, while newer blood-based technologies provide another non-invasive option for eligible average-risk adults. This transition is broadening the range of screening modalities available to patients and increasing the importance of convenience and accessibility in screening programs.
Emergence of Blood-Based Molecular Screening Technologies
The market is increasingly incorporating blood-based molecular technologies that analyze circulating tumor-derived DNA and related biological signals. These tests are designed to provide a less invasive screening option for average-risk populations and can potentially address barriers associated with stool collection and endoscopic procedures. Regulatory acceptance of blood-based screening is therefore expanding the technological landscape of colorectal cancer detection.
Lower Screening Age Recommendations Expand the Eligible Population
The lowering of the recommended starting age for average-risk colorectal cancer screening expands the population eligible for routine screening and creates additional demand for screening tests, laboratory services, imaging, and follow-up procedures. Earlier screening also increases the importance of convenient testing methods that can encourage participation among adults who may not otherwise undergo preventive screening.
Need for Colonoscopy After Abnormal Non-Invasive Results Limits Standalone Screening Convenience
Non-invasive screening methods do not eliminate the need for diagnostic colonoscopy when results are abnormal. Patients receiving positive stool, blood-based, or other non-invasive screening results generally require colonoscopy to determine the presence and extent of disease and, where appropriate, remove lesions. This additional procedure can increase healthcare utilization and may reduce the perceived convenience advantage of non-invasive screening.
Expansion of Blood-Based Screening Creates Opportunities for Molecular Diagnostic Providers
Blood-based screening creates opportunities for diagnostic companies developing molecular assays that can detect colorectal cancer-associated biological changes from blood samples. These technologies can be incorporated into routine healthcare visits without requiring bowel preparation or stool collection, potentially improving participation among people who avoid conventional screening methods. Providers that can demonstrate reliable detection while meeting regulatory and clinical requirements can address the large population that remains insufficiently screened.
Persistent Screening Gaps and Unequal Participation Challenge Market Expansion
The effectiveness of colorectal cancer screening programs depends not only on the availability of tests but also on participation, timely completion, and follow-up after abnormal results. Differences in healthcare access, awareness, socioeconomic conditions, and willingness to undergo screening can leave substantial portions of the eligible population unscreened. Screening providers therefore face the challenge of improving participation while ensuring that abnormal results lead to appropriate diagnostic evaluation.
Colonoscopy Segment Dominated the Market with 46.7% Share in 2025
The colonoscopy segment dominated the global colorectal cancer screening market with a 46.7% share in 2025. Colonoscopy is widely used for colorectal cancer screening because it allows healthcare professionals to examine the entire colon and identify suspicious growths or polyps. It also enables the removal of certain polyps during the same procedure, supporting its established role in screening programs.
Stool-based tests accounted for 35.8% and are growing at the highest CAGR of 6.9%. Their non-invasive nature, convenience, and suitability for at-home sample collection are supporting wider adoption. CT colonography provides a less invasive imaging-based screening option, while flexible sigmoidoscopy is used to examine the lower portion of the colon. Increasing awareness and screening participation are supporting colorectal cancer screening market growth across different test types.
Request Customizationto receive a tailored report.
Hospitals and Clinics Segment Dominated the Market with 61.5% Share in 2025
The hospitals and clinics segment dominated the global colorectal cancer screening market with a 61.5% share in 2025. These healthcare facilities perform a large number of screening and diagnostic procedures and provide access to gastroenterologists, imaging systems, laboratories, and other supporting medical infrastructure. Their ability to provide screening, diagnosis, and follow-up care continues to strengthen the segment's leading position.
Diagnostic imaging centres accounted for 27.8% and are growing at the highest CAGR of 6.6%. Increasing availability of advanced imaging technologies and growing use of CT colonography are supporting demand through these facilities.
Other end users accounted for 10.7% and contribute through specialized screening and diagnostic services. Expanding access to screening facilities is supporting colorectal cancer screening market demand.
Speak to an Analystto discuss market opportunities.
North America colorectal cancer screening market accounted for 38.4% of the global market, reaching USD 6.18 billion in 2025, and is projected to grow at a CAGR of 5.2% during the forecast period. Strong healthcare infrastructure, established cancer screening programs, and increasing awareness of early colorectal cancer detection are supporting regional demand. Growing adoption of colonoscopy, stool-based tests, and advanced non-invasive screening methods is further improving screening participation.
The US market was valued at USD 5.25 billion in 2025, making it the largest contributor in North America. Established screening programs, advanced diagnostic infrastructure, and increasing adoption of stool-based and minimally invasive testing methods continue to support market growth.
Canada's market reached USD 0.93 billion in 2025. Organized screening programs, increasing awareness of early diagnosis, and improved access to colorectal cancer testing are supporting market development.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe colorectal cancer screening market accounted for 29.1% of the global market, reaching USD 4.69 billion in 2025, and is expected to register a CAGR of 5.5% during the forecast period. Government-supported screening initiatives, aging populations, and growing awareness of colorectal cancer prevention are supporting regional demand. Increasing adoption of fecal immunochemical tests and colonoscopy-based screening is also improving early detection rates.
Germany's market accounted for USD 1.36 billion in 2025. Established cancer screening programs, advanced healthcare infrastructure, and increasing focus on preventive healthcare continue to support market growth.
The UK market was valued at USD 0.94 billion in 2025. Organized bowel cancer screening programs, increasing public awareness, and wider availability of home-based screening tests continue to contribute to market development.
Asia Pacific colorectal cancer screening market accounted for 22.3% of the global market, reaching USD 3.59 billion in 2025, and is projected to register the fastest regional CAGR of 7.4% during the forecast period. Improving healthcare infrastructure, increasing awareness of cancer prevention, aging populations, and expansion of screening programs are driving regional demand. Greater availability of non-invasive diagnostic tests is also encouraging participation in colorectal cancer screening.
Japan's market generated USD 0.65 billion in 2025. An aging population, established healthcare infrastructure, and strong focus on preventive cancer screening continue to support demand for colorectal cancer testing.
China's market accounted for USD 1.87 billion in 2025, making it a major contributor within Asia Pacific. Expanding healthcare access, increasing colorectal cancer awareness, growing screening initiatives, and adoption of advanced diagnostic technologies continue to drive market growth.
Middle East & Africa colorectal cancer screening market accounted for 4.1% of the global market, reaching USD 0.66 billion in 2025, and is anticipated to grow at a CAGR of 5.9% during the forecast period. Improving healthcare infrastructure, increasing cancer awareness, and growing investment in diagnostic services are supporting regional development.
The UAE market was valued at USD 0.24 billion in 2025. Advanced healthcare facilities, increasing preventive health initiatives, and greater awareness of early colorectal cancer detection continue to support screening adoption.
The global Colorectal Cancer Screening market is highly competitive, driven by growing awareness of early cancer detection, increasing screening programs, and rising adoption of non-invasive diagnostic methods. Key players include Exact Sciences Corp., Danaher Corp., DiaCarta, Eiken Chemical Co., Ltd., Freenome Holdings Inc., Fujifilm Holdings Corp., GI-View, Guardant Health, Hangzhou Novahealth Technology Co., Ltd., Laboratory Corporation of America Holdings, Lepu Medical Technology (Beijing) Co., Ltd., Mainz Biomed N.V., Novigenix SA, Olympus Corp., Quest Diagnostics Inc., and QuidelOrtho Corp. Companies are focusing on stool-based tests, blood-based screening, molecular diagnostics, advanced imaging, and AI-supported technologies to improve early detection and patient convenience.
Exact Sciences Corp.: An Emerging Market Leader
Exact Sciences has strengthened its position through its non-invasive colorectal cancer screening and molecular diagnostic solutions. The company focuses on improving early cancer detection, increasing screening accessibility, and developing convenient testing options that encourage greater patient participation. These capabilities support Exact Sciences’ strong position in the global colorectal cancer screening market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Bronchoscopes Market Size, Share, Growth, Analysis, Report, 2034
Aesthetic Threads Market Size, Share, Growth, Forecast, 2034
Aerosol Delivery Devices Market Size, Share, Growth, 2034
Artificial Cornea and Corneal Implant Market Size, Share, 2034
Active Wheelchair Market Size, Share, Growth, Forecast, 2034
Alpha Emitter Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com